LONDON – Pharmaceutical company Midatech Pharma PLC (MTPH.LN) said Wednesday that it has signed a global licensing agreement with Novartis AG (NOVN.EB) for the oncology compound panobinostat.
Continue Reading Below
The company intends to develop panobinostat for the treatment of brain tumor.
Shares at 0741 GMT trading 4.4% higher at 108 pence.
Write to Tapan Panchal at email@example.com
(END) Dow Jones Newswires
June 07, 2017 03:59 ET (07:59 GMT)